Efficacy and Safety of Postnatal Betamethasone for Respiratory Weaning in Extremely Low Gestational Age Neonates (ELGANs) in a Prospective Cohort - Proof of Concept Pilot Study
Overview
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Khang Nguyen
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- The rate of successful respiratory weaning
Overview
Brief Summary
The goal of this study is to determine if giving a steroid medication (specifically, betamethasone) after birth can help extremely premature babies (born before 28 weeks) come off breathing machines safely and reduce their risk of chronic lung disease associated with prematurity. Only babies who meet treatment criteria will receive this medication. Babies who do not meet treatment criteria will not receive medication.
The main questions it aims to answer are:
- Does betamethasone make it easier for babies to come off a breathing machine?
- Does betamethasone cause any harmful side effects on growth or development?
All babies in this study will:
- Receive standard NICU care, with or without betamethasone
- Have their progress, growth, and development followed over time
Detailed Description
Babies born extremely early (before 28 weeks of pregnancy) often have very immature lungs and usually need a breathing machine to stay alive. Many of these babies develop a chronic lung disease associated with prematurity called bronchopulmonary dysplasia, which can cause breathing problems that may last for months or years.
Doctors sometimes use steroid medications after birth to help reduce lung inflammation, make breathing easier, and help babies come off the ventilator sooner. One of these medications is betamethasone. Betamethasone is already commonly given to mothers before preterm birth to help babies' lungs mature.
At our hospital, betamethasone has been given after birth for more than 20 years to help some premature babies breathe better and come off a breathing machine. This study will help us learn how well this medicine works and possible side effects.
All babies born before 28 weeks gestation will be approached for enrollment in this study. Babies with lung disease severe enough according to predetermined criteria will receive betamethasone. Babies who dont have severe lung disease will not receive betamethasone.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- — to 28 Weeks (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Infants born at less than 28 weeks gestation age
- •Admitted to WMC NICU prior to day of life 35
Exclusion Criteria
- •Infants with major congenital or chromosomal abnormalities.
- •Death prior to DOL
- •Previous exposure to postnatal steroids
Arms & Interventions
Betamethasone arm
Infants who meet clinical criteria will receive postnatal betamethasone
Intervention: Betamethasone (Drug)
Comparison
Infants who do not meet criteria to receive treatment
Outcomes
Primary Outcomes
The rate of successful respiratory weaning
Time Frame: From initiation of treatment until 7 days after treatment completion
* Defined by a 20% reduction from baseline in mean airway pressure or FiO2 if patient remains intubated * or successful extubation and maintenance of extubation for 7 days after betamethasone completion
Secondary Outcomes
- The incidence of adverse events(During betamethasone administration period (5 days))
- The incidence of adverse events(From the time of initiation of betamethasone until the time of NICU discharge or 52 weeks of age, whichever comes first)
- The incidence of adverse events(During betamethasone administration period and up to 72 hours after completion of betamethasone administration)
- The incidence of mortbidities associated with extreme prematurity(From admission until the time of NICU discharge or 52 weeks of age, whichever comes first)
- Anthropometric measurements(From discharge to 24 months corrected age)
- Neurodevelopmental outcomes(at 24 months corrected age)
- Bronchopulmonary dysplasia diagnosis(at 36 weeks corrected age)
Investigators
Khang Nguyen
MD
New York Medical College